MDCO The Medicines Company

39.14
-0.25  -1%
Previous Close 39.39
Open 39.22
Price To book 5.43
Market Cap 2.78B
Shares 71,072,000
Volume 1,884,595
Short Ratio 7.10
Av. Daily Volume 1,781,950

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial design agreed to by FDA - noted April 26, 2017.
Inclisiran
Hypercholesterolemia
Development discontinued due to poor effiacy - November 7, 2016.
MDCO-216 - MILANO-PILOT
Acute coronary syndrome (ACS)
Phase 3 data met endpoints June 2016. NDA filing due early 2017
CARBAVANCE
Complicated urinary tract infections (cUTI)
CRL April 30 2014. Approved June 22 2015
Cangrelor
Reduction of thrombotic cardiovascular events including stent thrombosis in patients with coronary artery disease undergoing percutaneous coronary intervention (PCI)
Approved April 30, 2015.
RAPLIXA
Hemostasis
Approved April 30, 2015.
IONSYS
Acute postoperative pain
Approved August 6 2014 under priority review.
Oritavancin
ABSSSI

Latest News

  1. Regeneron Presents Positive Phase II Data on HoFH Candidate
  2. ETFs with exposure to The Medicines Co. : May 22, 2017
  3. This Fund’s Picks Gained 200% In A Year And Why No One Knows About It
  4. The Medicines Co. :MDCO-US: Earnings Analysis: Q1, 2017 By the Numbers : May 9, 2017
  5. Alnylam (ALNY) Q1 Loss Wider than Expected, Revenues Up Y/Y
  6. Do Options Traders Know Something About Medicines Company (MDCO) Stock We Don't?
  7. The Medicines Company to Participate in the Bank of America Merrill Lynch 2017 Health Care Conference
  8. Edited Transcript of MDCO earnings conference call or presentation 26-Apr-17 12:30pm GMT
  9. The Medicines Company (MDCO) Q1 Loss Wider Than Expected
  10. Blog Coverage Medicines Co. Reaches Agreement with FDA for the Phase III Trial for Inclisiran
  11. Amgen Trips Amid Rivals: Sales Miss By $100 Million, But Earnings Top
  12. The Medicines Co. – Value Analysis (NASDAQ:MDCO) : April 26, 2017
  13. Medicines Co. reports 1Q loss
  14. The Medicines Company Reports First-Quarter 2017 Financial Results
  15. The Medicines Company and Alnylam Pharmaceuticals Announce Agreement with FDA on Phase III Clinical Program for Inclisiran
  16. The Medicines Co. breached its 50 day moving average in a Bearish Manner : MDCO-US : April 25, 2017
  17. Drug Stocks Q1 Earnings Releases on Apr 26: AMGN, GSK & More
  18. The Medicines Company to Present Data at ECCMID 2017 on Infectious Disease Portfolio Including Investigational Antibiotic Meropenem-Vaborbactam
  19. The Medicines Company to Announce First-Quarter 2017 Financial Results on April 26, 2017